A comparison of pharmacoepidemiological study designs in medication use and traffic safety research

European Journal of Epidemiology

Volumn 27, Issue 6, 2012, Pages 473-481

  Ravera, Silvia ^a   Van Rein, Nienke ^a   De Gier, Johan J ^a   De Jong Van Den Berg, Lolkje T W ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

Case control study; Case crossover study; Case time control study; Pharmacoepidemiology; Psychotropic medications; Road traffic accidents

Indexed keywords

ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; HYPNOTIC AGENT; NEUROLEPTIC AGENT; SEDATIVE AGENT; SEROTONIN UPTAKE INHIBITOR;

ARTICLE; AUTUMN; CASE CONTROL STUDY; CONTROLLED STUDY; DATA BASE; DEMOGRAPHY; DRUG EXPOSURE; DRUG USE; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MEDICAL RESEARCH; PHARMACOEPIDEMIOLOGY; RISK ASSESSMENT; SEASONAL VARIATION; SPRING; SUMMER; TRAFFIC ACCIDENT; TRAFFIC SAFETY; WINTER;

ACCIDENTS, TRAFFIC; ADULT; ANTIPSYCHOTIC AGENTS; CASE-CONTROL STUDIES; CROSS-OVER STUDIES; DRUG UTILIZATION; FEMALE; HUMANS; MALE; MIDDLE AGED; RESEARCH DESIGN; RISK ASSESSMENT; SEASONS; TRANQUILIZING AGENTS;

EID: 84863720823     PISSN: 03932990     EISSN: 15737284     Source Type: Journal    
DOI: 10.1007/s10654-012-9689-3     Document Type: Article

References (32)

1. de Gier JJ, Alvarez FJ, Mercier-Guyon C, Verstraete AG. Prescribing and dispensing guidelines for medicinal drugs affecting driving performance. In: Verster JC, Pandi-Perumal SR, Ramaekers JG, de Gier JJ, editors. Drugs, Driving and Traffic Safety. Basel, Boston, Berlin: Birkaeuser Verlag AG; 2009. p. 121-34.
2. Drummer OH. The role of drugs in road safety. Australian Prescriber. 2008;31:33-5.
3. Orriols L, Salmi LR, Philip P, Moore N, Delorme B, Castot A, et al. The impact of medicinal drugs on traffic safety: A systematic review of epidemiological studies. Pharmacoepidemiol Drug Saf. 2009;18:647-58.
4. Raes E, van den Neste T, Verstraete AG. Drug use, impaired driving and traffic accidents-EMCDDA Insights. Available at: Http://www.emcdda.europa.eu/ publications/insights/driving (Last access: July 2011).
5. Walsh JM, de Gier JJ, Christopherson AS, Verstraete AG. Drugs and driving. Traffic Inj Prev. 2004;5:241-53.
6. Hemmelgarn B, Suissa S, Huang A, Boivin JF, Pinard G. Benzodiazepine use and the risk of motor vehicle crash in the elderly. JAMA. 1997;278:27-31.
7. Barbone F, McMahon AD, Davey PG, Morris AD, Reid IC, McDevitt DG, et al. Association of road-traffic accidents with benzodiazepine use. Lancet. 1998;352:1331-6.
8. Hebert C, Delaney JA, Hemmelgarn B, Levesque LE, Suissa S. Benzodiazepines and elderly drivers: A comparison of pharmacoepidemiological study designs. Pharmacoepidemiol Drug Saf. 2007;16:845-9.
9. Ravera S, van Rein N, de Gier JJ, de Jong-van den Berg LTW. Road traffic accidents and psychotropic medication use in the Netherlands: A case-control study. Br J Clin Pharmacol. 2011;72:505-13.
10. Strom BL. Pharmacoepidemiology. 2nd ed. Chichester, West Sussex: Wiley; 1994.
11. Hennekens CH, Buring JE Epidemiology in Medicine. Lippincott Williams and Wilkins, Philadelphia. 1987.
12. Neas LM, Schwartz J, Dockery D. A case-crossover analysis of air pollution and mortality in Philadelphia. Environ Health Perspect. 1999;107:629-31.
13. Maclure M. The case-crossover design: A method for studying transient effects on the risk of acute events. Am J Epidemiol. 1991;133:144-53.
14. Maclure M, Mittleman MA. Should we use a case-crossover design? Annu Rev Public Health. 2000;21:193-221.
15. Maclure M, Mittleman MA. Case-crossover designs compared with dynamic follow-up designs. Epidemiology. 2008;19(2): 176-8.
16. Petridou E, MittlemanMA, Trohanis D, Dessypris N, Karpathios T, Trichopoulos D. Transient exposures and the risk of childhood injury: A case-crossover study in Greece. Epidemiology. 1998;9: 622-5.
17. Ravera S, Visser ST, de Gier JJ, de Jong-van den Berg LT. Prevalence, cumulative incidence, monotherapy and combination therapy, and treatment duration of frequently prescribed psychoactive medications in the Netherlands: Retrospective database analysis for the years, 2000 to 2005. Clin Ther. 2010;32:2457-66.
18. Suissa S. The case-time-control design. Epidemiology. 1995;6: 248-53.
19. Zambon A, Polo Friz H, Contiero P, Corrao G. Effect of macrolide and fluoroquinolone antibacterials on the risk of ventricular arrhythmia and cardiac arrest: An observational study in Italy using case-control, case-crossover and case-time-control designs. Drug Saf. 2009;32:159-67.
20. Suissa S. The case-time-control design: Further assumptions and conditions. Epidemiology. 1998;9:441-5.
21. Movig KL, Mathijssen MP, Nagel PH, van Egmond T, de Gier JJ, Leufkens HG, et al. Psychoactive substance use and the risk of motor vehicle accidents. Accid Anal Prev. 2004;36:631-6.
22. Hernandez-Diaz S, Hernan MA, Meyer K, Werler MM, Mitchell AA. Case-crossover and case-time-control designs in birth defects epidemiology. Am J Epidemiol. 2003;158:385-91.
23. Toh S, Mitchell AA, Anderka M, Hernandez-Diaz S, de Jong-van den Berg LT. National Birth Defects Prevention Study. Antibiotics and oral contraceptive failure-A case-crossover study. Contraception. 2011;83:418-25.
24. PHARMO Institute (http://www.pharmo.nl) (Last access: July 2011).
25. Dienst Verkeer en Scheepvaart-DVS (http://www.rijkswater staat.nl/dvs) (Last access: July 2011).
26. Rijks Dienst Wegverkeer- RDW (http://www.rdw.nl/) (Last access: July 2011).
27. Del Rio MC, Alvarez FJ. Medication use by the driving population. Pharmacoepidemiol Drug Saf. 1996;5:255-61.
28. WHO Collaborating Centre for Drug Statistics Methodology. Available at: Http://www.whocc.no/ddd/definition-and-general-considera/ (Last access: July 2011).
29. Maclure M. 'Why me?' versus 'why now?'-Differences between operational hypotheses in case-control versus case- crossover studies. Pharmacoepidemiol Drug Saf. 2007;16:850-3.
30. Schneeweiss S, Sturmer T, Maclure M. Case-crossover and case- time-control designs as alternatives in pharmacoepidemiologic research. Pharmacoepidemiol Drug Saf. 1997;6(Suppl 3):S51-9.
31. Guess HA. Exposure-time-varying hazard function ratios in case- control studies of drug effects. Pharmacoepidemiol Drug Saf. 2006;15:81-92.
32. Greenland S. Confounding and exposure trends in case-crossover and case-time-control designs. Epidemiology. 1996;7:231-9.